In the last trading session, 1.01 million shares of the Karyopharm Therapeutics Inc (NASDAQ:KPTI) were traded, and its beta was 0.09. Most recently the company’s share price was $0.62, and it changed around -$0.01 or -1.28% from the last close, which brings the market valuation of the company to $78.61M. KPTI currently trades at a discount to its 52-week high of $1.70, offering almost -174.19% off that amount. The share price’s 52-week low was $0.58, which indicates that the current value has risen by an impressive 6.45% since then. We note from Karyopharm Therapeutics Inc’s average daily trading volume that its 10-day average is 0.69 million shares, with the 3-month average coming to 886.03K.
Karyopharm Therapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.57. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 1 recommended KPTI as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Karyopharm Therapeutics Inc is expected to report earnings per share of -0.27 for the current quarter.
Karyopharm Therapeutics Inc (NASDAQ:KPTI) trade information
Instantly KPTI has showed a red trend with a performance of -1.28% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.6850 on recent trading dayincreased the stock’s daily price by 9.49%. The company’s shares are currently down -7.90% year-to-date, but still up 0.13% over the last five days. On the other hand, Karyopharm Therapeutics Inc (NASDAQ:KPTI) is -13.00% down in the 30-day period. We can see from the shorts that 19.8 million shares have been sold at a short interest cover period of 17.52 day(s).
The consensus price target as assigned by Wall Street analysts is $5, which translates to bulls needing to increase their stock price by 87.6% from its current value. Analyst projections state that KPTI is forecast to be at a low of $3 and a high of $14.
Karyopharm Therapeutics Inc (KPTI) estimates and forecasts
The year-over-year growth rate is expected to be 3.01%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 35.67M in revenue for the current quarter. 3 analysts expect Karyopharm Therapeutics Inc to make 37.83M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 33.75M and 33.13M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 5.71%. Forecasts for the next quarter put sales growth at 14.19%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 16.79%. Karyopharm Therapeutics Inc earnings are expected to increase by 45.03% in 2025, but the outlook is positive 24.25% per year for the next five years.
KPTI Dividends
Karyopharm Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 6.20% of Karyopharm Therapeutics Inc shares, and 47.27% of them are in the hands of institutional investors. The stock currently has a share float of 50.40%. Karyopharm Therapeutics Inc stock is held by 109.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 6.6299% of the shares, which is about 7.65 million shares worth $6.64 million.
PALO ALTO INVESTORS LP, with 4.4192% or 5.1 million shares worth $4.43 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
